Eisbach
Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors.
$4.50M
Latest Funding
Seed
Latest Funding Stage
2024-03-21
Funding Date
14
Employees
Germany
Location
Munich, Bayern
City & State
Sales-Ready Summary
Eisbach Bio recently raised $4.5M in Seed funding and is hiring a Chief Medical Officer, suggesting they are expanding their team and focusing on clinical development. Companies offering services for clinical trial management, regulatory compliance, or medical affairs should reach out.
Key Contacts
Open Positions
View Careers PageHiring For
Similar Startups
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development.
Arsenale Bioyards
Arsenale is transforming biomanufacturing with a proprietary end-to-end platform that integrates advanced hardware, AI-driven software, and precision fermentation. Designed to bridge the gap from lab-scale innovation to industrial-scale production, Arsenale enables industries like food, chemicals, and materials to seamlessly develop and scalebio-based alternatives to petrochemicals and animal-derived products.
Avitia
Avitia improves cancer treatment via advanced molecular testing solutions. Avitia offer testing tools for use on-site, bioinformatics driven by AI, and actionable insights aimed at enhancing patient outcomes. Avitia offerings comprise pre-prepared NGS panels, simplified reporting mechanisms, and cooperative diagnostic platforms.
Ignota Labs
Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions.